EVALUATION OF CIS AND TRANS-9 AND XY-5,6,6A,7,8,12B-HEXAHYDROBENZO[A]PHENANTHRIDINES AS STRUCTURALLY RIGID, SELECTIVE D-1 DOPAMINE-RECEPTORLIGANDS

Citation
Wk. Brewster et al., EVALUATION OF CIS AND TRANS-9 AND XY-5,6,6A,7,8,12B-HEXAHYDROBENZO[A]PHENANTHRIDINES AS STRUCTURALLY RIGID, SELECTIVE D-1 DOPAMINE-RECEPTORLIGANDS, Journal of medicinal chemistry, 38(2), 1995, pp. 318-327
Citations number
47
Categorie Soggetti
Chemistry Medicinal
ISSN journal
00222623
Volume
38
Issue
2
Year of publication
1995
Pages
318 - 327
Database
ISI
SICI code
0022-2623(1995)38:2<318:EOCATA>2.0.ZU;2-N
Abstract
The present study reports the investigation of the D-1 structure-relat ionships of certain cis- or traits-9- or 11-monohydroxy analogues of ( +/-)-trans-10,11-dihydroxy-5,6,6a,7,8,12 drobenzo[a]phenanthridine (8a , dihydrexidine), previously identified as the first full efficacy D-1 dopamine receptor agonist. The monohydroxybenzo[a]phenanthridines wer e prepared from the appropriately substituted beta-tetralones using th e methods described earlier for the synthesis of their catechol analog ues. The 10-bromo 11-hydroxy derivative se was prepared by treatment o f precursor 9c with bromine in chloroform. The affinities of these com pounds for the D-1 and De dopamine receptor classes and for their effe cts on adenylate cyclase activity were assessed in rat striatal membra nes. In addition to producing only minimal increases in adenylate cycl ase activity (less than or equal to 15%), these phenolic derivatives g enerally had significantly lower affinities for D-1 and D-2 receptors (D-1 IC50 greater than or equal to 102 nM, D-2 IC50 greater than or eq ual to 210 nM) than did their catechol analogues. Further, compounds b earing a cis B/C-ring fusion displayed lower affinities than those bea ring a trans configuration, paralleling the activity differences betwe en the catechol analogues. The data for these rigid dopamine receptor ligands from the benzo[a]phenanthridine class lend additional support for the hypothesis that D-1 agonist activity is optimized by a trans r ing configuration that maintains the beta-phenyldopamine substructure in the ''trans-beta-rotamer.''